• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Aging (Albany NY) >Short-term efficacy of ticagrelor in acute ST-segment elevation myocardial infarction patients undergoing an emergency percutaneous coronary intervention
【2h】

Short-term efficacy of ticagrelor in acute ST-segment elevation myocardial infarction patients undergoing an emergency percutaneous coronary intervention

机译：替格瑞洛在急诊经皮冠状动脉介入治疗急性ST段抬高型心肌梗死患者中的近期疗效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In total, 97 acute ST-segment elevation myocardial infarction (STEMI) patients who received an emergency percutaneous coronary intervention (PCI) were enrolled and divided into a ticagrelor group and a clopidogrel group. Thrombolysis in myocardial infarction (TIMI) blood flow and the corrected TIMI frame count (CTFC) were used to assess the blood perfusion of culprit vessels. Thromboelastography (TEG) was used to evaluate the antiplatelet effect of drugs. The results showed that the incidence of TIMI grade III blood flow in the ticagrelor group was significantly higher than that in the clopidogrel group. The CTFC in the anterior descending, circumflex, and right coronary arteries was statistically significantly lower in the ticagrelor group as compared with that in the clopidogrel group. At 2 h and 7 d postdrug treatment, the adenosine diphosphate-induced platelet inhibition rate (ADP%) in the ticagrelor group increased significantly as compared with that in the clopidogrel group, and the platelet aggregation rate of the ADP pathway (MA ) decreased significantly in the ticagrelor group versus that in the clopidogrel group. In conclusion, ticagrelor significantly improved TIMI blood flow and had a better antiplatelet effect than clopidogrel in STEMI patients undergoing an emergency PCI.
机译：总共纳入了接受紧急经皮冠状动脉介入治疗（PCI）的97例急性ST段抬高型心肌梗死（STEMI）患者，并将其分为替卡格雷组和氯吡格雷组。心肌梗塞（TIMI）血流的溶栓和校正的TIMI框架计数（CTFC）用于评估罪犯血管的血液灌注。血栓弹力图（TEG）用于评估药物的抗血小板作用。结果显示替卡格雷组的TIMI III级血流发生率显着高于氯吡格雷组。与氯吡格雷组相比，替卡格雷组的前降支，回旋支和右冠状动脉的CTFC在统计学上显着降低。药物治疗后2 h和7 d，替卡格雷组与氯吡格雷组相比，替卡格雷组的二磷酸腺苷诱导的血小板抑制率（ADP％）明显增加，而ADP途径（MA）的血小板聚集率显着下降替卡格雷组与氯吡格雷组相比。总之，在接受急诊PCI的STEMI患者中，替加格雷洛显着改善了TIMI血流并具有比氯吡格雷更好的抗血小板作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号